N/A N=17

Cytokines in Papillon-Lefèvre Syndrome

Papillon-Lefevre Disease

Bottom Line

View on ClinicalTrials.gov: NCT01116934 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2016

Primary outcome: Primary: Serum Concentrations of Interleukin (IL)-1 Beta — 1100.00; 896.21; 65559; 45734 pg/ml

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Goethe University
Primary completion: Jan 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Serum Concentrations of Interleukin (IL)-1 Beta	1100.00; 896.21; 65559; 45734; 12902.5; 11563	—

Summary

Papillon-Lefèvre syndrome (PLS) is characterised by aggressively progressive periodontitis combined with palmo-plantar hyperkeratosis. It is caused by "loss of function" mutations in the cathepsin C gene. The hypothesis behind this study is that PLS patients' PMNs produce more proinflammatory cytokines to compensate for their reduced capacity to neutralize leukotoxin and to eliminate Aggregatibacter actinomycetemcomitans. Production of more interleukin (IL)-8 would result in the attraction of more PMNs. Thus, the aim of this study was to evaluate the cytokine profile in PLS patients' blood cultures.

Eligibility Criteria

Inclusion Criteria

Diagnose of PLS

Exclusion Criteria

No written informed consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01116934). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.